The Effect of Intravenous Magnesium Sulfate on Intraocular Pressure Following Tracheal Intubation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01241175
Recruitment Status : Completed
First Posted : November 16, 2010
Last Update Posted : November 16, 2010
Information provided by:
Shiraz University of Medical Sciences

Brief Summary:
The aim of this study is to assess the effect of preoperatively administered intra venous magnesium sulfate in attenuating pressure response to laryngoscopy and endotracheal intubation in adult patients scheduled for elective non ocular surgery

Condition or disease Intervention/treatment Phase
Increased Intra Ocular Pressure (IOP) Drug: Magnesium Sulfate Drug: normal saline Phase 3

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Masking: Double (Care Provider, Outcomes Assessor)
Primary Purpose: Prevention

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: magnesium sulfate Drug: Magnesium Sulfate
Placebo Comparator: normal saline Drug: normal saline

Primary Outcome Measures :
  1. Intra ocular pressure

Secondary Outcome Measures :
  1. blood pressure,heart rate

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 38 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 to 38 years old
  • ASA I
  • scheduled for elective ENT ambulatory surgeries under general anesthesia

Exclusion Criteria:

  • specific major hepatic, renal and cardio-vascular disease
  • known to have allergic reaction to magnesium sulphate or other drugs , -hypermagnesemia
  • hypocalcemia
  • anuria
  • heart block
  • pregnancy
  • any degree of renal insufficiency
  • digitalised patients
  • positive history of glaucoma or intra ocular hypertension
  • refused to participate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01241175

Iran, Islamic Republic of
Shiraz University of Medical Sciences
Shiraz, Fars, Iran, Islamic Republic of
Sponsors and Collaborators
Shiraz University of Medical Sciences
Study Director: Hilda Mahmoudi, M.D Shiraz University of Medical Sciences Identifier: NCT01241175     History of Changes
Other Study ID Numbers: 4286
First Posted: November 16, 2010    Key Record Dates
Last Update Posted: November 16, 2010
Last Verified: March 2009

Keywords provided by Shiraz University of Medical Sciences:
ophthalmic anesthesia
magnesium sulfate

Additional relevant MeSH terms:
Magnesium Sulfate
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Depressants
Anti-Arrhythmia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Tocolytic Agents
Reproductive Control Agents